View Products These assay achieve high levels of sensitivity for the study of GLP-1 analogs
Federal law technically prohibits importation, but individual shipments for personal use are rarely prosecuted
Toll-like receptor signaling in cell proliferation and survival
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
References: [1] Pietra C, et al
Semaglutide additionally raises insulin levels to enhance glycemic control, reinforcing satiety and promoting homeostatic eating [8, 9]